Compare Cronos Group Inc (CRON) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Kimberly Clark Corp — how do they compare? Cronos Group Inc trades at $3.22 (market cap $1.18B), while Kimberly Clark Corp trades at $97.97 (market cap $32.51B). The key difference: Kimberly Clark Corp is far larger — about 27.6× Cronos Group Inc's market cap, and Kimberly Clark Corp pays a 5.24% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Kimberly Clark Corp for 93 Days on average.
| CRON | KMB | |
|---|---|---|
Market Cap | $1.18B | $32.51B |
Volume | 968,037 | 6,139,913 |
Sector | Health | Consumer Staples |
52-Week High | $3.55 | $121.44 |
52-Week Low | $2.30 | $93.05 |
Typical Hold Time | 22 Days | 93 Days |
Enterprise Value | $387.62M | $38.07B |
Dividend Yield | — | 5.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.24, down 1.37% today amid a bearish technical signal. Recent quarterly earnings show beats in Q1 and Q2 2026, with revenue growth from $118M in 2024 to $147M in 2025. The company reported a net loss of $9.45M in 2025 but projects a profit of $70M for 2026. Analyst sentiment is mixed with a 20% buy rating. News highlights focus on international expansion and a recent Investor Day outlining growth strategies.
Outlook is cautiously optimistic given projected profitability in 2026 and strong cash reserves, but risks include sustained negative cash flow and competitive pressures. The stock's valuation metrics like P/E of 16.95 and P/S of 6.84 suggest moderate pricing relative to peers, though high EV/EBITDA of 43 indicates premium expectations.
Kimberly-Clark (KMB) trades at $96.48, down 0.3% on the day, showing bearish technical signals with the current price near support at $96. The company maintains strong profitability with 11.79% net margins and has beaten earnings estimates in 2 of the last 3 quarters, though Q2 2026 missed expectations. Recent executive transitions and the pending Kenvue acquisition create both strategic opportunities and integration risks.
KMB offers a compelling 5.3% dividend yield with 54 consecutive years of increases, but cash flow concerns and acquisition-related debt pose sustainability questions. Analyst consensus remains cautiously optimistic with a $117.25 price target suggesting 21% upside, though the stock faces near-term headwinds from technical weakness and merger execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
